跳至主要内容
临床试验/KCT0000732
KCT0000732已完成未知

A 12 week, multi-center, randomized, double-blind, placebo-controlled, parallel, phase II trial to evaluate the efficacy and safety of WIN-34B in patients with Osteoarthritis of the knee

Hamsoa Pharmaceutical0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
35(Year) 至 80(Year)(—)
性别
All

入选标准

  • 1) Being between 35 and 80 years of age
  • 2) Diagnosised with Osteoarthritis of the knee at least 3 months
  • 3) Diagnosised with Osteoarthritis of the knee, based on ACR criteria
  • 4) Able to communicate with researchers and write questionnaire
  • 5) At the screening visit, checking 100mm Pain VAS at least 80mm
  • 6) At randomization(Visit 2), checking 100mm Pain VAS over 50mm
  • 7) Agreeing to participate and signing informed consent voluntarily

排除标准

  • 1) Previous intra-articular injection on knee within 3 months
  • 2) Previous knee surgery within 6 months or scheduled procedures
  • 3) Other diseases that could affect or interfere with the therapeutic outcomes
  • 4) Experiencing habitual use of psychotropic, narcotic analgesic drugs over 1 week
  • 5) Diagnosised with gastrointestinal diseases, unable to stop medicines during the study
  • 6) At the screening visit, identified liver dysfunction
  • 7) At the screening visit, identified renal dysfunction
  • 8) Patients who cannot take NSAIDs
  • 9) Pregnancy and breast-feeding (women of childbearing age need pregnancy test)
  • 10) Physicological or mental disorders, including drug-takers
  • 11) Orthopedic diseases that could affect or interfere with the therapeutic outcomes
  • 12) Inappropriate for the study

研究者

发起方
Hamsoa Pharmaceutical

相似试验

A 12 week, phase II trial to evaluate the efficacy... | 临床试验